Study drug for multiple myeloma after several prior treatments
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and your myeloma has relapsed or is refractory after at least 3 prior treatment “lines.”
- Your disease must have measurable signs (for example, a certain level of M protein or abnormal free light chains, or enough abnormal plasma cells in bone marrow).
- You do not have myeloma in the brain or spinal fluid (CNS involvement).
- You’re well enough to participate (ECOG 0–2).
- Your recent treatments fit the timing rules (at least 2 weeks since radiation or systemic therapy; certain investigational-agent gaps also apply).
- Your organs and heart/lungs meet safety thresholds (blood count/chemistry limits, heart pumping function above a set level, and oxygen level at least 92% on room air).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a new treatment called BAFF CAR-T cells for people with certain types of lymphoma or multiple myeloma that have come back or not responded to standard treatments. The treatment uses your own immune cells, modified in the lab to find and attack cancer cells, and is given as an infusion. The goal is to see if this can help control the disease when other options haven't worked.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This study tests a new type of immune cell therapy (CAR T-cells) for people with advanced multiple myeloma that has relapsed or not responded to standard treatments. The goal is to see if this therapy is safe and to understand its potential benefits.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.